Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
Krystal Biotech (NASDAQ:KRYS) announced its participation in the upcoming Cantor Global Healthcare Conference 2025, taking place in New York on September 4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ:KRYS) announced its participation in the upcoming Cantor Global Healthcare Conference 2025, taking place in New York on September 4, 2025. Chairman and CEO Krish S. Krishnan will participate in a fireside chat at 10:20 AM ET and conduct investor meetings throughout the day.
The presentation will be accessible via webcast and will be made available on the Investors section of the company's website.
Details
News Market Reaction – KRYS
On Sep 2, the day this news came out, KRYS closed 0.88% above the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:20 am ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 10:20 am ET on Thursday, September 4, 2025 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.